RESEARCH ARTICLE

Prevalence of COVID-19 vaccine reactogenicity among Bangladeshi physicians

Md. Anwarul Azim Majumder1,2 | Afzalunnessa Binte Lutfor3 | Abhob Mohammad Fazle Rabbi4 | A. B. M. Muksudul Alam5 | Mizanur Rahman6 | Narayan Saha7 | Michael H. Campbell2 | Mainul Haque8 | Kamrun Nessa9 | Mohib Ullah Khondoker10 | Tapas Ranjan Das11 | Sayeeda Rahman12 | Fauzia Jahan13 | Saidur Rahman Mashreky14 | Abrar Wahab14 | Md. Tosaddeque Hossain Siddiqui15 | Karisha Hinkson-Lacorbiniere2 | Roksana Ivy5 | Rezaul Islam16 | Yusuf Haider17 | Eliza Omar5 | S. M. Mosleuddin Ahmed18 | A. M. Selim Reza5 | A. K. M. Daud19 | Muiz Uddin Ahmed Choudhury19 | Md. Abed Hossain19 | Abdul Matin Pappu5 | Nusrat Jahan20 | Mohammed S. Razzaque21

1Public Health Foundation of Bangladesh, Dhaka, Bangladesh
2The University of the West Indies, Bridgetown, Barbados
3Ad-Din Women's Medical College, Dhaka, Bangladesh
4Bangladesh University of Textiles, Dhaka, Bangladesh
5Shaheed Suhrawardy Medical College, Dhaka, Bangladesh
6International Medical College, Dhaka, Bangladesh
7National Institute of Neurosciences & Hospital, Dhaka, Bangladesh
8National Defence University of Malaysia, Kuala Lumpur, Malaysia
9Chittagong Medical College, Chittagong, Bangladesh
10Gonoshasthaya Samaj Wittik Medical College, Dhaka, Bangladesh
11Sheikh Sayera Khatun Medical College, Gopalganj, Bangladesh
12American University of Integrative Sciences, Bridgetown, Barbados
13Bangladesh Medical College, Dhaka, Bangladesh
14Centre for Injury Prevention and Research Bangladesh (CIPRB), Dhaka, Bangladesh
15Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
16Shaheed Monsur Ali Medical College Hospital, Dhaka, Bangladesh
17Colonel Malek Medical College, Manikganj, Bangladesh
18Uttara Adhunik Medical College Dhaka, Dhaka, Bangladesh
19Jalalabad Ragib-Rabeya Medical College, Sylhet, Bangladesh
20United Hospital Ltd, Dhaka, Bangladesh
21Lake Erie College of Osteopathic Medicine, Pennsylvania, USA

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2022 The Authors. FASEB BioAdvances published by the Federation of American Societies for Experimental Biology
1 | INTRODUCTION

Recent studies have demonstrated that high rates of COVID-19 vaccine hesitancy among both the general population and healthcare professionals (HCPs) present a major hurdle in global efforts to contain the COVID-19 pandemic. In the absence of sufficient vaccine acceptance, universal access to vaccination may not achieve immunization coverage essential to control the ongoing pandemic. In fact, global herd immunity (population vaccine coverage of 60%–80%) is becoming unachievable due to stark disparities in vaccination rates among different countries. As of 23 February 2022, more than 4.9 billion vaccine doses have been administered worldwide, which is equal to 63.9% of the world population.

Several countries have temporarily discontinued the Oxford-AstraZeneca vaccine over concerns that the vaccine may be linked to an increased risk of blood clots. Although blood clots have been reported as an infrequent side effect in some populations, the risk of clotting due to COVID-19 infection appears to be greater than that posed by the vaccine. Nonetheless, these concerns may contribute to vaccine hesitancy. In addition to these rare, serious complications, more commonly reported symptoms associated with reactogenicity may also contribute to vaccine reluctance.

The reactogenicity of COVID-19 vaccines is emerging. Thus far, data on vaccine safety and adverse events has been obtained primarily from manufacturer-sponsored studies. A few clinical trials have published short-term findings of the efficacy and safety of COVID-19 vaccines. Various government agencies monitor vaccine reactogenicity to rapidly detect safety ranges and rare adverse events, as well as provide real-time data for risk analysis and decision-making. For example, the U.S. Centers for Disease Control and Prevention (CDC) and the U.K. Medicines & Healthcare products Regulatory Agency (MHRA) collect self-reported data from vaccine recipients via online tools. Despite the recognized challenges of self-reporting symptoms, including inconsistency of data, reporting biases and lack of control groups, health authorities frequently use this approach to make inferences about the
wider population of vaccine recipients. Bangladesh started vaccination for COVID-19 from 8 February 2021. To our knowledge, this study is the first to report the prevalence and severity of COVID-19-vaccine associated reactogenicity among physicians in Bangladesh.

The current study aimed to estimate the prevalence of the AstraZeneca vaccine reactogenicity among physicians who received vaccinations in the initial phase of vaccine roll-out in Bangladesh. We surveyed only physicians and excluded other contemporary vaccine recipients to document reactogenicity in professionals with training to identify and clearly articulate symptoms. Monitoring the reactogenicity of COVID-19 vaccines has the potential to identify uncommon adverse responses particular to Bangladeshi cohorts. Documenting reactogenicity is crucial for planning necessary clinical supports following COVID-19 vaccination in Bangladesh and establishing safety data to promote vaccine acceptance.

2 | MATERIALS AND METHODS

2.1 | Study design and participants

A cross-sectional survey was conducted among physicians working in different government and private sector academic institutes and hospitals in Bangladesh. Inclusion criteria were physicians who received at least one dose of the AstraZeneca COVID-19 vaccine. The study was conducted from 12 April 2021 to 31 May 2021.

2.2 | Data collection

We asked physicians to complete a self-administered online survey (via the Google Docs® platform) adapted for Bangladesh from an instrument developed by researchers working in Barbados (Hinkson-Lacoriniere and team). The questionnaire was validated by a multinational panel of public health specialists and amended as per their suggestions. A pilot study was conducted among 29 respondents who were excluded from the formal evaluation, and further adjustment was done based on their inputs.

The modified questionnaire included demographic information, vaccination status (single dose or both required doses), history of COVID-19 infection and presence of comorbidities (including diabetes, hypertension, lung disease, kidney disease and cancer). Vaccine reactogenicity was recorded in terms of time of symptom onset (same day, 1–3 days post-vaccination, 4–7 post-vaccination), severity (Severe—I had to seek medical attention; Moderate—I had to stop my daily activities; Mild—I was still able to do most daily activities), duration (1 day, 2–3 days, 4–7 days, still present) and whether treatment measures were taken (yes, no). Additionally, the questionnaire elicited physicians’ awareness of thromboembolic events and thrombocytopenia following vaccination.

The survey was conducted and reported based on the checklist for reporting results of internet e-surveys (CHERRIES). Because the survey was time sensitive, we recruited participants using convenience sampling by sharing the survey link via social networks (Facebook, Messenger, WhatsApp and Viber) and e-mail. Investigators took the advantage of social media groups, professional associations and healthcare organizations to promote the survey.

Participation in the survey was voluntary and anonymous. All the participants gave consent before participation. No identifiable personal information was collected or stored.

2.3 | Ethical approval

Prior ethical approval was granted by the Research Ethics Committee of Shaheed Suhrawardy Medical College, Dhaka, Bangladesh (No: ShSMCH/Ethical/2021/09).

2.4 | Statistical analysis

We calculated the reported prevalence of reactogenic events and their relationship with recorded demographic information. The primary outcome variable of interest was the presence of reactogenicity following COVID-19 vaccination. Further, bivariate analyses were performed to examine the link between existing comorbidities, demographic characteristics and reported adverse events. Multivariate logistic regression was performed to investigate the individual effects of predictor variables on reactogenic symptoms. All statistical analysis was performed using IBM SPSS 22.

3 | RESULTS

3.1 | Responders’ characteristics

The demographic characteristics of the participants are shown in Table 1. A total of 916 physicians completed the questionnaire. The majority of respondents were male (52.8%) and were employed in the public/government sector (60.6%). Many of the respondents (35%) were those between 31-40 years. More than half of the respondents (52.2%) reported no history of chronic diseases. More than a quarter of respondents (28.5%) had tested positive for COVID-19 infection, and
about three-quarters (78.3%) had received both first and second doses of COVID-19 vaccination at the time of the survey. All participants received the Covishield (AstraZeneca) vaccine, which was the only available vaccine in Bangladesh during the study period.

### 3.2 Prevalence of vaccine reactogenicity

The prevalence of vaccine reactogenicity among respondents is shown in Figure 1. More than 58% (n = 533) respondents reported one or more reactogenic symptoms. The six most commonly reported adverse events were
“soreness of the injected arm” (71.9%), “tiredness” (56.1%), “fever” (54.4%), “soreness of muscles” (48.4%), “headache” (41.5%) and “sleeping more than usual” (26.8%). Most respondents characterized the severity of symptoms as mild. However, some respondents did rate their experience of symptoms as severe. The most common severe symptoms were fever (9.4%) and tiredness (20.1%). Only 11.5% of the respondents recalled similar adverse events from previous vaccinations for other diseases (e.g., BCG, HPV).

Approximately half (49.2%) of the respondents took acetaminophen to treat reactogenic symptoms. Other actions taken to treat symptoms were sleep (23.1%) and drinking water (22.4%). More than 75% of the respondents were aware of the risk of thromboembolic events, and more than half (55.5%) were mindful of thrombocytopenia.

The observed types of reactogenicity, including onset and duration, are summarized in Table 2. For most respondents, these adverse events appeared on the same day of vaccination, except for tiredness (24%), which appeared 2–3 days post vaccination. For 46.5% of participants, soreness in the arm occurred on the same day of vaccination; same-day fever was reported by 34.3% of respondents. However, most respondents reported duration of 1–3 days for these frequently observed reactogenicities. For 45.8% of participants, soreness in the arm lasted for 1–3 days, followed by fever (31.5%). Tiredness persisted for 7 days for 7.7% of participants and beyond 7 days for 3.9%.

The prevalence of reactogenicity among physicians stratified by gender and age is shown in Table 3. Females reported a higher incidence of reactogenicity compared to males. Fever, vision trouble, sleeping more than usual, rash/itching over the injected arm, and nausea were significantly more common among females ($p < 0.05$). Most of the adverse events were reported by respondents <45 years, irrespective of gender. Adverse events classified as “other” are shown in Appendix 1. Four case studies describing these reports are contained in Appendix 2.

3.3 Determinants of adverse events

Findings from binary logistic regression analyses are presented in Table 4. All age groups had a significant impact on having adverse events than the physicians with younger age group. Physicians aged 61–70 years were almost 96% less likely to have an adverse event than physicians in their twenties (OR = 0.041 with 95% CI lies between 0.016 and 0.105). Existing comorbidity has an impact on having adverse events as well. Physicians with diabetes and hypertension were 2.72 times more likely to have an adverse event than physicians without prior conditions. Asthma and other comorbidities (OR = 1.885 95% CI: 1.001–3.551) also significantly increased the risk of reactogenicities than physicians without comorbidities.

4 DISCUSSION

The study estimated the prevalence of reactogenicity after the first dose of the AstraZeneca vaccine among Bangladeshi physicians. To the best of our knowledge, this is the first study of its type in Bangladesh. A key strength of this survey is the accuracy and reliability of symptom reporting by medical professionals. We found that
over half (58.2%) of respondents reported at least one reactogenic side effect after the first dose of vaccine. Two studies of the general population in Bangladesh at approximately the same time as the current study reported similar prevalence of adverse events: 50.9% in February-June 2021 and 54.1% in May 2021. Compared to Bangladesh, higher vaccine reactogenicity has been reported in studies of HCPs in India (65.9% and 69.7%), South Korea (99.8%, 98.1%, 90.9%, and 93%), Germany, Czech Republic (94.6%), Togo (71.6%), Nepal (85%), Saudi Arabia (96.1%), Ethiopia (68.4%) and Ghana (80.7%). However, lower rates were found among HCPs in two studies from India—40% and 56.9%. These disparities may be due to greater representation of elderly participants (≥65 years), as older adults generally exhibit milder symptoms. Jeon et al. noted the higher incidence (0% vs. 8.9%) and greater severity of reactogenic events in a younger age group compared to a study conducted by Voysey et al. with participants ≥65 years. In the present study, 5.8% of respondents were ≥60 years old, which may be one of the reasons for lower reported adverse events. Further, our study found that physicians aged 61–70 years were almost 96% less likely to have adverse events than physicians in their twenties. Similar age-related findings were reported in other studies of Covisheild, Pfizer-BioNTech and Moderna vaccine recipients.

Reactogenicity is usually induced by innate and adaptive immune responses leading to the release of chemokine and cytokines. Reactogenic symptoms are the result of chemokines and cytokines that mimic systemic immune response and include fever, tiredness, fatigue, pain and headache. Similarly, the release of inflammatory mediators due to immune response at the injection site leads to local reactions. These symptoms are evidence of effective vaccination. The most commonly reported reactogenicity in our study was pain at the injection site, which was more prevalent among females and younger respondents. These findings are consistent with those of previous studies on the vaccination of HCPs. The most common reactogenicity reported in our study coincides with other studies conducted among HCPs and studies conducted among the general population. As in other studies, most of our respondents experienced mild symptoms that were self-limiting and resolved within a few days (1–3 days). Approximately half of the respondents took acetaminophen to treat symptoms, which is more than reported in other recent studies. One-quarter of respondents in a general-population Bangladeshi study used acetaminophen to minimize vaccine-associated discomfort, as did 33.3% of HCPs in an Ethiopian study.

We found that fever, vision trouble, sleeping more than usual, rash/itching over the injected arm and nausea were

| Time of appearance | Duration adverse events last | The severity of adverse events | The most commonly reported reactogenic symptoms (n = 533) |
|--------------------|-----------------------------|------------------------------|---------------------------------------------------------|
| Between 1-3 days   | 244 (45.8%)                 | Severe 30 (5.6%)              | 30 (5.6%)                                              |
|                   | 65 (12.2%)                  | Moderate 87 (16.3%)           | 87 (16.3%)                                             |
|                   | 279 (52.3%)                 | Mild 124 (23.7%)              | 124 (23.7%)                                            |
|                   | 57 (10.7%)                  | Total 290 (54.4%)             | 290 (54.4%)                                            |
| Between 2-3 days   | 258 (48.4%)                 | Soreness of the injected arm 84 (15.8%) | 84 (15.8%) |
|                   | 147 (27.6%)                 | Soreness of muscles 62 (11.5%) | 62 (11.5%) |
|                   | 153 (28.7%)                 | Fever 133 (24.8%)             | 133 (24.8%)                                            |
|                   | 290 (54.4%)                 | Headache 137 (25.5%)          | 137 (25.5%)                                            |
|                   | 107 (20.1%)                 | Tiredness 157 (29.5%)         | 157 (29.5%)                                            |
|                   | 70 (13.1%)                  | Sleeping more than usual 143 (26.8%) | 143 (26.8%) |
| Same day           | 24 (46.5%)                  | Soreness of the injected arm 34 (6.4%) | 34 (6.4%) |
|                   | 128 (24.8%)                 | Soreness of muscles 4 (0.8%)  | 4 (0.8%) |
|                   | 166 (31.5%)                 | Fever 168 (31.5%)             | 168 (31.5%)                                            |
|                   | 153 (28.7%)                 | Headache 172 (32.2%)          | 172 (32.2%)                                            |
|                   | 290 (54.4%)                 | Tiredness 182 (34.3%)         | 182 (34.3%)                                            |
|                   | 258 (48.4%)                 | Sleeping more than usual 233 (43.8%) | 233 (43.8%) |
| >7 days            | 229 (43.0%)                 | Soreness of the injected arm 50 (9.4%) | 50 (9.4%) |
|                   | 160 (30.6%)                 | Soreness of muscles 39 (7.3%) | 39 (7.3%) |
|                   | 168 (31.5%)                 | Fever 281 (52.2%)             | 281 (52.2%)                                            |
|                   | 153 (28.7%)                 | Headache 203 (38.1%)          | 203 (38.1%)                                            |
|                   | 299 (56.1%)                 | Tiredness 246 (46.2%)         | 246 (46.2%)                                            |
|                   | 65 (12.2%)                  | Sleeping more than usual 111 (20.9%) | 111 (20.9%) |
|                   | 65 (12.2%)                  | Severe 35 (6.6%)              | 35 (6.6%)                                              |
|                   | 107 (20.1%)                 | Moderate 34 (6.4%)            | 34 (6.4%)                                              |
|                   | 70 (13.1%)                  | Mild 34 (6.4%)                | 34 (6.4%)                                              |
|                   | 57 (10.7%)                  | Total 169 (31.8%)             | 169 (31.8%)                                            |
more commonly reported by females ($p < 0.05$). From the detailed frequency distribution, we found that female physicians experienced vaccine reactogenicity earlier than their male counterparts and that symptoms usually disappeared within 1–3 days in female physicians (not shown in tables of result section). Studies demonstrated that increased experience of adverse vaccination-related events in women is related to estradiol, which can induce a more robust immune responses following vaccination.\cite{45,46} Females typically exhibit higher innate, humoral and cellular immune responses to viral infections as well as in response to vaccines.\cite{47} Specific manifestations of gender differences in immune response have been documented in several studies. Females tend to have more robust immune responses due to greater generation of antibodies and a more robust T-cell response.\cite{48} Further, females exhibit higher levels of antibody response, humoral response and cell-mediated immune response to antigenic stimulation, vaccination and infection.\cite{49} This higher vaccine reactogenicity is associated with higher basal and post-vaccination IgG levels and increased B cell numbers and functions compared to men.\cite{47,50} Finally, higher body fat content in females may reduce the distribution and clearance of medications.\cite{51}

We found that existing comorbidities increased the likelihood of adverse reactogenic events. Physicians with “diabetes and hypertension” and “obesity and other complications” had a double risk of reactogenicity. A recent general-population Bangladeshi study reported similar findings with an odds ratio of reactogenic symptoms after the first vaccine dose of 1.8 for participants with comorbidities.\cite{36} Despite an increased risk of adverse vaccine reactions, people with underlying medical conditions are also at increased risk of COVID-19 infections.\cite{52} The World Health Organization (WHO) Strategic Advisory Group of Experts (SAGE) on Immunization clinical trials with the Oxford-AstraZeneca (Covishield) vaccine (AZD1222) concluded that people with comorbidities (obesity, cardiovascular disease, respiratory disease and diabetes) had an increased risk of severe COVID-19.\cite{53} For most people with comorbidities, the benefits of COVID-19 vaccination outweigh the risks of adverse events.

In Appendix 1, we list the adverse events reported by respondents in the ‘other’ categories. Earlier studies have not revealed some of these infrequent adverse events (e.g., cracked teeth, meningismus, severe eye pain, menstrual irregularities including spotting, excessive menstrual bleeding, decreased urine output and hematuria).

| TABLE 3 | Prevalence of reactogenic symptoms among physicians stratified by gender and age |
|---------|---------------------------------|
|         | Gender                          | Age                      |
|         | Male ($n = 269$) | Female ($n = 264$) | Total | $p$-value | 21–44 years old$^a$ | 45+ years old$^a$ | Total | $p$-value |
| Adverse events | | | | | ($n = 370$) | ($n = 160$) | | |
| Soreness of the injected arm | 200 (74.3%) | 199 (75.4%) | 399 | 0.518 | 303 (81.9%) | 94 (58.8%) | 397 | 0.092 |
| Soreness of muscles | 136 (50.1%) | 127 (48.1%) | 263 | 0.678 | 197 (53.2%) | 64 (40.0%) | 261 | 0.486 |
| Fever | 147 (54.7%) | 147 (55.7%) | 294 | 0.007* | 218 (58.9%) | 74 (46.3%) | 292 | 0.101 |
| Headache | 114 (42.4%) | 110 (41.7%) | 224 | 0.257 | 168 (45.4%) | 56 (35.0%) | 224 | 0.398 |
| Vision trouble | 6 (2.2%) | 13 (4.9%) | 19 | 0.039* | 16 (4.3%) | 3 (1.9%) | 19 | 0.729 |
| Tiredness | 148 (55.0%) | 159 (60.2%) | 307 | 0.090 | 236 (63.8%) | 70 (43.8%) | 306 | 0.919 |
| Sleeping more than usual | 66 (24.5%) | 83 (31.4%) | 149 | 0.076 | 118 (31.9%) | 30 (18.8%) | 148 | 0.407 |
| Sleeping less than usual | 22 (8.2%) | 22 (8.3%) | 44 | 0.925 | 31 (8.4%) | 13 (8.1%) | 44 | 0.039* |
| Sleeping more than usual | 3 (1.1%) | 8 (3.0%) | 11 | 0.038* | 7 (1.9%) | 4 (2.5%) | 11 | 0.750 |
| Had more energy | 6 (2.2%) | 4 (1.5%) | 10 | 0.422 | 9 (2.4%) | 1 (0.6%) | 10 | 0.558 |
| Less anxious | 21 (7.8%) | 14 (5.3%) | 35 | 0.103 | 25 (6.8%) | 10 (6.3%) | 35 | 0.241 |
| Swelling of the injected arm | 31 (11.5%) | 48 (18.2%) | 79 | 0.023 | 69 (18.6%) | 10 (6.3%) | 79 | 0.164 |
| Swelling all over/allergic reaction | 3 (1.1%) | 6 (2.3%) | 9 | 0.407 | 7 (1.9%) | 2 (1.3%) | 9 | 0.912 |
| Rash/itching over the injected arm | 4 (1.4%) | 16 (6.0%) | 20 | 0.003* | 15 (4.0%) | 5 (3.2%) | 20 | 0.768 |
| Diarrhea | 12 (4.4%) | 16 (6.0%) | 28 | 0.499 | 19 (51.4%) | 8 (5.0%) | 27 | 0.464 |
| Nausea | 20 (7.43%) | 33 (12.5%) | 53 | 0.038* | 44 (11.9%) | 9 (5.6%) | 53 | 0.586 |
| Vomiting | 6 (2.2%) | 9 (3.4%) | 15 | 0.426 | 13 (3.5%) | 2 (1.3%) | 15 | 0.915 |

$^a$ 21–44 years: Younger participants.

$^b$ 45+ years: Older participants.

*$^*$ Significance: $p < 0.05$. 
Because these are idiosyncratic events, their clinical significance is unclear. We present four case studies of clinically significant adverse events (Appendix 2). One of the surveyed physicians complained of sudden vertigo and lost consciousness for a few seconds which occurred 2.5 h following vaccination. After regaining consciousness, ECG suggested acute myocardial infraction, and the physician required surgical intervention for blockage in the left anterior descending artery. Another physician reported menstrual irregularities with spotting lasting for 15 days. Severe neck pain and severe pain while walking (spasm of bilateral quadriceps muscles) were experienced by another physician. The last case study describes the experience of vertigo and orthostatic hypotension starting immediately after vaccination and persisting for 3 days. These unusual complications should be carefully documented, but their relationship to immunization is not established. Similarly, a UK-based phase 2/3 trial identified 13 serious adverse events (SAEs), but none were established to be related to vaccination.39 Voysey et al.39 reported 175 SAEs occurring in 168 of 11,636 participants, of which only three events were shown to be related to vaccination.

4.1 Study limitations

Because of sampling limitations, there is a possibility that survey results might not generalize to the entire HCP population of Bangladesh. However, since all participants were physicians, we believe that their reporting of reactogenicity is exceptionally accurate. This study design

| TABLE 4 Logistic regression coefficients and odds ratios (95% CI) for determinants reactogenic symptoms |
|-----------------|-----------------|-----------------|-----------------|-----------------|
| Variables | β | SE (β) | Exp(β) with 95% CI |
| Gender of respondent | | | |
| Male (ref) | | | |
| Female | −0.007 | 0.158 | 0.993 (0.729, 1.353) |
| Age of respondents (in years) | | | |
| 21–30 (ref) | | | |
| 31–40 | −0.762** | 0.264 | 0.467 (0.278, 0.783) |
| 41–50 | −1.243*** | 0.280 | 0.289 (0.167, 0.500) |
| 51–60 | −1.842*** | 0.321 | 0.159 (0.084, 0.298) |
| 61–70 | −3.205*** | 0.484 | 0.041 (0.016, 0.105) |
| Work type of respondents (detailed) | | | |
| Medical college/hospital (ref) | | | |
| Medical university/hospital | −0.077 | 0.294 | 0.926 (0.521, 1.647) |
| Private hospital | 0.223 | 0.245 | 1.250 (0.773, 2.021) |
| District hospital | 0.802* | 0.418 | 2.231 (0.984, 5.058) |
| Government specialized hospital | −0.306 | 0.249 | 0.737 (0.452, 1.200) |
| Upazilla health complex | 0.571 | 0.372 | 1.771 (0.855, 3.669) |
| Institute of health technology | 0.924 | 1.121 | 2.520 (0.280, 22.677) |
| Dental college | −1.492 | 1.218 | 0.225 (0.021, 2.446) |
| Others | −0.039 | 0.276 | 0.962 (0.560, 1.651) |
| Prior presence of any chronic illness | | | |
| No illness (ref) | | | |
| Diabetes | 0.130 | 0.434 | 1.139 (0.486, 2.667) |
| Diabetes; Hypertension | 1.004** | 0.385 | 2.729 (1.282, 5.089) |
| Diabetes; Hypertension and other diseases | 0.304 | 0.457 | 1.356 (0.554, 3.319) |
| Diabetes and other diseases | 0.726 | 0.614 | 2.066 (0.620, 6.880) |
| Hypertension and other diseases | 0.194 | 0.213 | 1.214 (0.799, 1.842) |
| Obesity and other diseases | 0.707* | 0.422 | 2.027 (0.886, 4.636) |
| Asthma and other diseases | 0.634* | 0.323 | 1.885 (1.001, 3.551) |
| Other diseases | 0.483 | 0.435 | 1.621 (0.691, 3.802) |

Note: Reference category is denoted by (ref). Significance: ***p < 0.01, **p < 0.05, *p < 0.1.
explicitly does not address the general population. Broader multicentric studies are required to obtain a true picture of reactogenicity in the general population after both or booster doses of vaccination. Additionally, we evaluated only short-term reactogenicity, and surveillance will be needed to determine possible long-term effects of vaccination. More robust probability sampling will provide better understanding of prevalence and underlying causes of reactogenic and other adverse vaccination-related events.

5 | CONCLUSION

The majority of vaccine recipients in our study reported reactogenicity, but symptoms were mild and of short duration. The most common reactogenic symptoms were pain at the injection site and tiredness. Reactogenicity was reported more frequently among females and younger age groups. Vaccine recipients and healthcare staff should be aware of possible reactogenicity and management protocols to ensure that vaccination benefits are maximized relative to risks. Further studies on vaccine safety are required for monitoring and to assure the public regarding safety of available vaccines.

ACKNOWLEDGMENTS

The authors thank the physicians who consented to participate in this study and completed the questionnaire.

CONFLICT OF INTEREST

The authors have no conflict of interest to declare.

AUTHOR CONTRIBUTIONS

Majumder MAA, Lutfor AB, Razzaque MS, Alam ABMM; planned & designed the study. Lutfor AB, Alam ABMM, Majumder MAA, Siddiqui MTH, Nessa K, Khondoker MU, Rahman M, Saha N, Jahan F, Ivy R, Islam R, Haider Y, Haque M, Omar E, Ahmed SMM, Reza AMS, Daud AKM, Choudhury MUA, Hossain MA, Rahman S, Pappu AM: actively collected the data. Majumder MAA, Lutfor AB, Razzaque MS, Mashreky SR, Rahman S, Rabbi AMF, Wahab A: wrote the manuscript. Rabbi AMF, Mashreky SR, Wahab A, Majumder MAA: analyzed the data. Hinkson-Lacorbiniere K: developed the original questionnaire and edited the manuscript. Majumder MAA, Lutfor AB, Razzaque MS, Mashreky SR, Rahman S, Rabbi AMF & Wahab A: Modified the questionnaire. Campbell MH: critically read the manuscript, edited the manuscript & provided useful suggestions on data analysis. All authors: critically reviewed the manuscript and approved the final draft. Majumder MAA, Lutfor AB, MuAlam ABMM have full access to all the data and take responsibility for the integrity of the data.

ORCID

Md. Anwarul Azim Majumder ⓒ https://orcid.org/0000-0003-3398-8695
Afzalunnessa Binte Lutfor ⓒ https://orcid.org/0000-0002-0176-8746
A. B. M. Muxudul Alam ⓒ https://orcid.org/0000-0002-7309-8382
Mizanur Rahman ⓒ https://orcid.org/0000-0002-3827-4678
Narayan Saha ⓒ https://orcid.org/0000-0003-3779-2788
Michael H. Campbell ⓒ https://orcid.org/0000-0002-5927-2612
Mainul Haque ⓒ https://orcid.org/0000-0002-6124-7993
Sayeeda Rahman ⓒ https://orcid.org/0000-0002-7005-8801
Saidur Rahman Mashreky ⓒ https://orcid.org/0000-0001-7892-798X
Yusuf Haider ⓒ https://orcid.org/0000-0002-5864-180X
Nusrat Jahan ⓒ https://orcid.org/0000-0002-8420-8196
Mohammed S. Razzaque ⓒ https://orcid.org/0000-0003-1115-4550

REFERENCES

1. Alam ABMM, Azim Majumder MA, Haque M, et al. Disproportionate COVID-19 vaccine acceptance rate among healthcare professionals on the eve of nationwide vaccine distribution in Bangladesh. Expert Rev Vaccines. 2021;20(9):1167-1175.
2. Solís Arce JS, Warren SS, Meriggi NF, et al. COVID-19 vaccine acceptance and hesitancy in low- and middle-income countries. Nat Med. 2021;27:1385-1394.
3. Krishnamurthy K, Sobers N, Kumar A, et al. COVID-19 Vaccine intent among Health Care Professionals of Queen Elizabeth Hospital, Barbados. J Multidiscip Healthc. 2021;14:3309-3319.
4. Ashok N, Krishnamurthy K, Singh K, Rahman S, Majumder MAA. High COVID-19 vaccine hesitancy among healthcare workers: should such a trend require closer attention by policymakers? Cureus. 2021;13(9):e17990.
5. Kabir R, Mahmud I, Chowdhury MTH, et al. COVID-19 vaccination intent and willingness to pay in Bangladesh: a cross-sectional study. Vaccines (Basel). 2021;9(5):416.
6. Kaplan RM, Milstein A. Influence of a COVID-19 vaccine’s effectiveness and safety profile on vaccination acceptance. Proc Natl Acad Sci U S A. 2021;118(10):e2021726118.
7. Tracking Coronavirus Vaccinations Around the World. The New York Times; 2021. https://www.nytimes.com/interactive/2021/world/covid-vaccinations-tracker.html
8. Mandavilli A. Reaching ‘Herd Immunity’ is unlikely in the U.S., experts now believe. The New York Times 2021.
9. France24. Covid-19: Why countries are suspending AstraZeneca vaccinations. France24 2021.
10. World Health Organization. Statement of the WHO Global Advisory Committee on Vaccine Safety (GACVS) COVID-19 subcommittee on safety signals related to the AstraZeneca COVID-19 vaccine. 2021; https://www.who.int/news/item/19-03-2021-statement-of-the-who-global-advis
ory-committee-on-vaccine-safety-(gaevs)-covid-19-subcommittee-on-safety-signals-related-to-the-astrazeneca-covid-19-vaccine

11. European Medicines Agency. COVID-19 Vaccine AstraZeneca: benefits still outweigh the risks despite possible link to rare blood clots with low blood platelets. 2021; https://www.ema.europa.eu/en/news/covid-19-vaccine-astrazeneca-benefits-still-outweigh-risks-despite-possible-link-rare-blood-clots

12. GOV.UK. UK regulator confirms that people should continue to receive the COVID-19 vaccine. AstraZeneca; 2021. https://www.gov.uk/government/news/uk-regulator-confirms-that-people-should-continue-to-receive-the-covid-19-vaccine-astrazeneca#full-publication-update-history

13. Pormohammad A, Zarei M, Ghorbani S, et al. Efficacy and safety of COVID-19 vaccines: a systematic review and meta-analysis of randomized clinical trials. Vaccines. 2021;9(3):467.

14. Riad A, Pokorná A, Attia S, Klugarová J, Koščík M, Klugar M. Prevalence of COVID-19 vaccine side effects among healthcare workers in the Czech Republic. J Clin Med. 2021;10(7):1428.

15. Rahman S, Montero MTV, Rowe K, Kirton R, Kunik F Jr. Epidemiology, pathogenesis, clinical presentations, diagnosis and treatment of COVID-19: a review of current evidence. Expert Rev Clin Pharmacol. 2021;14(5):601-621.

16. CDC. Ensuring COVID-19 Vaccine Safety in the US. 2021; https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety.html

17. CDC. V-safe After Vaccination Health Checker. 2021; https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/vsafe.html

18. MHRA. Yellow Card Vaccine Monitor. 2021; https://vaccinejournals.gov.uk/yellowcard.mhra.gov.uk/

19. Follegati PM, Ewer KJ, Aley PK, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020;396(10249):467-478.

20. Smith B, Chu LK, Smith TC, et al. Challenges of self-reported medical conditions and electronic medical records among members of a large military cohort. BMC Med Res Methodol. 2008;8:37.

21. Eysenbach G. Improving the quality of Web surveys: the Checklist for Reporting Results of Internet E-Surveys (CHERRIES). J Med Internet Res. 2004;6:e34.

22. Kamal D, Thakur V, Nath N, Malhotra T, Gupta A, Batlish R. Adverse events following ChAdOx1 nCoV-19 Vaccine (COVISHIELD) amongst health care workers: a prospective observational study. Med J Armed Forces India. 2021;77(Suppl 2):S283-s288.

23. Cuscieri S, Borg M, Agius S, Souness J, Brincat A, Grech V. Adverse reactions to Pfizer-BioNTech vaccination of healthcare workers at Malta’s state hospital. Int J Clin Pract. 2021;75(10):e14605.

24. Sultana A, Shahriar S, Tahsin MR, et al. A retrospective cross-sectional study assessing self-reported Adverse Events following Immunization (AEFI) of the COVID-19 vaccine in Bangladesh. Vaccines (Basel). 2021;9(10):1090.

25. Khalil MM, Mahbub-Uz-Zaman K, Hossain A-S, et al. Adverse events following COVISHIELD vaccination among adult population in Bangladesh. SN Compr Clin Med. 2021;3(11):2207-2213.

26. Jayadevan R, Shenoy R, Ts A. Survey of symptoms following COVID-19 vaccination in India. medRxiv. 2021:2021.2002.2021.21251366.
professionals - a mixed method study. *Int Immunopharmacol*. 2021;100:108136.

43. Gautam A, Dangol N, Bhattarai U, et al. ChAdOx1 nCoV-19 vaccine and its self-reported adverse events: a cross-sectional study from Western Nepal. *J Glob Health Rep*. 2021;5:e2021069.

44. Solomon Y, Esthe T, Mekasha B, Assefa W. COVID-19 vaccine: side effects after the first dose of the Oxford AstraZeneca vaccine among health professionals in low-income country: Ethiopia. *J Multidiscip Healthc*. 2021;14:2577-2585.

45. Potluri T, Fink AL, Sylvia KE, et al. Age-associated changes in the impact of sex steroids on influenza vaccine responses in males and females. *NPJ Vaccines*. 2019;4:29.

46. Fischinger S, Boudreau CM, Butler AL, Streeck H, Alter G. Sex differences in vaccine-induced humoral immunity. *Semin Immunopathol*. 2019;41(2):239-249.

47. Ruggieri A, Anticoli S, D’Ambrosio A, Giordani L, Viora M. The influence of sex and gender on immunity, infection and vaccination. *Ann Ist Super Sanita*. 2016;52(2):198-204.

48. Fathi A, Addo MM, Dahlke C. Sex differences in immunity: implications for the development of novel vaccines against emerging pathogens. *Front Immunol*. 2020;11:601170.

49. Klein SL, Jedlicka A, Pekosz A. The Xs and Y of immune responses to viral vaccines. *Lancet Infect Dis*. 2010;10(5):338-349.

50. Flanagan KL, Fink AL, Plebanski M, Klein SL. Sex and gender differences in the outcomes of vaccination over the life course. *Annu Rev Cell Dev Biol*. 2017;33:577-599.

51. Lewis PJ, Catanzano TM, Davis LP, Jordan SG. Web-based conferencing: what radiology educators need to know. *Acad Radiol*. 2020;27(3):447-454.

52. CDC. Underlying Medical Conditions Associated with Higher Risk for Severe COVID-19: Information for Healthcare Providers. 2021; https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html Accessed Dec 2021

53. World Health Organization. Interim recommendations for use of the ChAdOx1-S [recombinant] vaccine against COVID-19 (AstraZeneca COVID-19 vaccine AZD1222 Vaxzevria™, SII COVISHIELD™), Geneva 2021.

54. Ramasamy MN, Minassian AM, Ewer KJ, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. *Lancet*. 2021;396(10267):1979-1993.

How to cite this article: Majumder MAA, Lutfur AB, Rabbi AMF, et al. Prevalence of COVID-19 vaccine reactogenicity among Bangladeshi physicians. *FASEB BioAdvances*. 2022;4:379–390. doi:10.1096/fba.2021-00158
APPENDIX 1

Adverse events reported in the “other” category

- Vertigo ($n = 3$)
- Orthostatic hypotension ($n = 1$)
- Myalgia ($n = 2$)
- Severe backache ($n = 2$)
- Cracked teeth ($n = 1$)
- Muscle cramp ($n = 2$)
- Joint pain ($n = 2$)
- Sore throat ($n = 2$)
- Meningismus ($n = 1$)
- Severe eye pain ($n = 1$)
- Severe backache radiating to both legs ($n = 1$)
- Dizziness ($n = 1$)
- Abdominal pain ($n = 1$)
- Menstrual irregularities including spotting ($n = 1$)
- Excessive menstrual bleeding ($n = 1$)
- Decreased urine output ($n = 1$)
- Migraine ($n = 1$)
- Palpitation ($n = 2$)
- Hematuria ($n = 1$)
- Severe thirst ($n = 1$)
- Unconsciousness ($n = 1$)

APPENDIX 2

Four case studies related to severe adverse events

**Case study 1**
Age: 63 years  
Gender: Male  
Co-morbidity: Diabetes  
Vaccine status: First dose only  
The participant received the vaccine at about 11 a.m. on 13.02.2021. About 2.5 h later, he had sudden vertigo with the tingling whole of the left upper extremity and immediately became unconscious for a few seconds. After gaining consciousness, he had severe bouts of vomiting. The participant had no chest pain, no compression chest, no dyspnoea, but exhibited profuse sweating. Tingling left upper extremity was persisting. He had an ECG with very high ST elevations suggesting acute myocardial infarction (AMI). He took Ecosprin 4, clopidogrel 4, Emistat 1 & anti-ulcerent. He then was rushed to Dhaka (capital city). On his way, initially, he felt chest compression and took Nitroglycerin sublingually. When he arrived in Dhaka, all of his discomforts disappeared, and he started to feel quite better. He had an angiogram which revealed two long segment blocks in the left anterior descending artery. Two days later, two stentings were done, and the patient returned home 2 days after surgery.  
Past history: He never had any dyspnoea, chest pain, compression, any sudden sweating or discomfort on going up (4 to 7/8 stairs at stress). He was a chain smoker of 20+ sticks/day. He was taking no medicine to control diabetes, which was always 10–14 mmol/L since 2006. He was not on exercise for diabetes mellitus.

**Case study 2**
Age: 28 years  
Gender: Female  
Co-morbidity: No illness  
Vaccine status: First dose only  
Her menstrual cycle changed. The menstrual cycle started 15 days after vaccination and lasted for 15 days. She had not experienced this previously. She was also experiencing spotting.

**Case study 3**
Age: 30 years  
Gender: Male  
Co-morbidity: Nonalcoholic fatty liver disease  
Vaccine status: Taken both dosages  
The participant experienced severe neck pain and had severe pain and spasms of the bilateral quadriceps muscles, causing unbearable pain while walking. The pain was relieved by hot compression, analgesics and topical Vollygel (diclofenac gel) application on affected muscles.

**Case study 4**
Age: 34 years  
Gender: Male  
Co-morbidity: No illness  
Vaccine status: Taken both dosages  
The respondent experienced vertigo and orthostatic hypotension, which started immediately after vaccination and lasted for 3 days.